Comerica Bank Ultragenyx Pharmaceutical Inc. Transaction History

Comerica Bank

$23.4 Billion
Q1 2025

A detailed history of Comerica Bank transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Comerica Bank holds 7,352 shares of RARE stock, worth $262,172. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,352

Previous 1,303 464.24%

Holding current value

$262,172

Previous $54,000 392.59%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$36.21 - $45.78 $219,034 - $276,923	6,049 Added 464.24%	7,352 $266,000
Q4 2024 Feb 14, 2025	SELL	$42.07 - $57.72 $9,297 - $12,756	-221 Reduced 14.5%	1,303 $54,000
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $15,923 - $23,506	396 Added 35.11%	1,524 $84,000
Q2 2024 Aug 15, 2024	SELL	$37.42 - $51.61 $9,766 - $13,470	-261 Reduced 18.79%	1,128 $46,000
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $2,495 - $3,114	58 Added 4.36%	1,389 $64,000
Q4 2023 Feb 14, 2024	BUY	$31.73 - $49.19 $8,376 - $12,986	264 Added 24.74%	1,331 $63,000
Q3 2023 Nov 21, 2023	SELL	$34.92 - $46.66 $51,960 - $69,430	-1,488 Reduced 58.24%	1,067 $38,000
Q2 2023 Aug 22, 2023	BUY	$37.35 - $52.15 $95,429 - $133,243	2,555 New	2,555 $16,000
Q2 2021 Aug 26, 2021	SELL	$92.19 - $115.71 $184,195 - $231,188	-1,998 Closed	0 $0
Q1 2021 Apr 28, 2021	SELL	$106.9 - $167.73 $20,097 - $31,533	-188 Reduced 8.6%	1,998 $227,000
Q4 2020 Jan 28, 2021	BUY	$84.4 - $177.39 $253 - $532	3 Added 0.14%	2,186 $302,000
Q3 2020 Oct 30, 2020	BUY	$72.98 - $90.0 $159,315 - $196,470	2,183 New	2,183 $179,000

Others Institutions Holding RARE

# of Institutions

336

Shares Held

88.9M

Call Options Held

1.08M

Put Options Held

1.04M

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.5B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.

Account